Wellington Management Group
CLDX icon

Wellington Management Group’s Celldex Therapeutics CLDX Stock Holding History

Wellington Management Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355M Buy
9,543,671
+983,195
+11% +$31.8M 0.06% 278
2026
Q1 		$272M Buy
8,560,476
+480,868
+6% +$13.1M 0.05% 312
2025
Q4 		$219M Buy
8,079,608
+2,279,605
+39% +$60M 0.04% 368
2025
Q3 		$150M Buy
5,800,003
+567,677
+11% +$13.2M 0.03% 454
2025
Q2 		$106M Sell
5,232,326
-3,121,825
-37% -$60.8M 0.02% 506
2025
Q1 		$152M Sell
8,354,151
-621,682
-7% -$13.9M 0.03% 417
2024
Q4 		$227M Sell
8,975,833
-267,766
-3% -$7.28M 0.04% 340
2024
Q3 		$314M Buy
9,243,599
+1,167,659
+14% +$44.5M 0.06% 293
2024
Q2 		$299M Buy
8,075,940
+428,483
+6% +$16.2M 0.05% 299
2024
Q1 		$321M Buy
7,647,457
+1,170,896
+18% +$48.1M 0.06% 307
2023
Q4 		$257M Buy
6,476,561
+1,044,728
+19% +$30.7M 0.05% 346
2023
Q3 		$149M Buy
5,431,833
+300,406
+6% +$9.42M 0.03% 437
2023
Q2 		$174M Buy
5,131,427
+949,816
+23% +$32M 0.03% 424
2023
Q1 		$150M Sell
4,181,611
-466,301
-10% -$20.1M 0.03% 451
2022
Q4 		$207M Buy
4,647,912
+1,567,179
+51% +$55.9M 0.04% 379
2022
Q3 		$86.6M Buy
3,080,733
+240,350
+8% +$7.37M 0.02% 555
2022
Q2 		$76.6M Sell
2,840,383
-689,457
-20% -$20M 0.02% 594
2022
Q1 		$120M Buy
3,529,840
+1,343,864
+61% +$43M 0.02% 550
2021
Q4 		$84.5M Buy
2,185,976
+5,624
+0.3% +$245K 0.01% 674
2021
Q3 		$118M Buy
2,180,352
+217,353
+11% +$10.2M 0.02% 581
2021
Q2 		$65.6M Buy
1,962,999
+74,263
+4% +$2.04M 0.01% 741
2021
Q1 		$38.9M Buy
1,888,736
+1,794,536
+1,905% +$41.2M 0.01% 884
2020
Q4 		$1.65M Buy
+94,200
New +$1.7M ﹤0.01% 1518
2014
Q2 		– Sell
-668
Closed -$177K – 2159
2014
Q1 		$177K Buy
+668
New +$256K ﹤0.01% 2117
2013
Q3 		– Sell
-107,872
Closed -$25.3M – 2176
2013
Q2 		$25.3M Buy
+107,872
New +$21.2M 0.01% 893

Other funds holding CLDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Wellington Management Group's CLDX Position: Q2 2026 in Review

Wellington Management Group increased its Celldex Therapeutics (CLDX) stake by 11% in Q2 2026, buying an estimated $31.8M and bringing the position to 9,543,671 shares worth $355M. The position accounts for 0.06% of the portfolio, ranked #278.

Wellington Management Group first reported a position in CLDX in Q2 2013 and has held it in 25 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Wellington Management Group held 9,543,671 shares of Celldex Therapeutics worth $355M as of Q2 2026.
  • Wellington Management Group bought 983,195 Celldex Therapeutics shares in Q2 2026, an estimated $31.8M.
  • Celldex Therapeutics made up 0.06% of Wellington Management Group's portfolio in Q2 2026, its #278 holding.
  • Wellington Management Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 25 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.